Effects of clinical breakpoint changes in CLSI guidelines 2010/2011 and EUCAST guidelines 2011 on antibiotic susceptibility test reporting of Gram-negative bacilli by Hombach, Michael et al.
Effects of clinical breakpoint changes in CLSI guidelines 2010/2011
and EUCAST guidelines 2011 on antibiotic susceptibility test
reporting of Gram-negative bacilli
Michael Hombach*, Guido V. Bloemberg and Erik C. Bo¨ttger
Institut fu¨r Medizinische Mikrobiologie, Universita¨t Zu¨rich, 8006 Zu¨rich, Switzerland
*Corresponding author. Tel: +41-44-634-27-00; Fax: +41-44-634-49-06; E-mail: mhombach@imm.uzh.ch
Received 22 September 2011; returned 7 November 2011; revised 10 November 2011; accepted 14 November 2011
Objectives: The aim of this study was to analyse the effects of clinical breakpoint changes in CLSI 2010 and
2011 guidelines and EUCAST 2011 guidelines on antibiotic susceptibility testing (AST) reports.
Methods: In total, 3713 non-duplicate clinical isolates of Enterobacteriaceae, Pseudomonas aeruginosa,
Stenotrophomonas maltophilia and Acinetobacter baumannii were analysed. Inhibition zone diameters were
determined for b-lactams, carbapenems, fluoroquinolones, aminoglycosides and trimethoprim/sulfamethoxazole.
CLSI 2009–11 and EUCAST 2011 clinical breakpoints were applied.
Results: Changes in resistance as defined per the guidelines affected individual species and drug classes differ-
ently. The cefepime resistance rate in Escherichia coli and Enterobacter cloacae increased from 2.1% and 1.3%
to 8.2% and 6.9%, respectively, applying CLSI 2009–11 versus EUCAST 2011 guidelines. Ertapenem resistance
rates in E. cloacae increased from 2.6% with CLSI 2009 to 7.2% for CLSI 2010 and 2011, and to 10.1% when
applying EUCAST 2011. Cefepime and meropenem resistance rates in P. aeruginosa increased from 12.2% and
20.6% to 19.8% and 27.7%, respectively, comparing CLSI 2009–11 with EUCAST 2011. Tobramycin and gen-
tamicin resistance rates in A. baumannii increased from 15.9% and 25.4% to 34.9% and 44.4% applying
CLSI 2009–11 versus EUCAST 2011.
Conclusions: Higher resistance rates reported due to breakpoint changes in CLSI and EUCAST guidelines will
result in increasing numbers of Gram-negative bacilli reported as multidrug resistant. AST reports classifying
amoxicillin/clavulanic acid, cefepime or carbapenem resistance will lead clinicians to use alternative agents.
Upon implementation of the EUCAST guidelines, laboratories should be aware of the implications of modified
drug susceptibility testing reports on antibiotic prescription policies.
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Introduction
The European Committee for Antimicrobial Susceptibility Testing
(EUCAST) has published guidelines for performance and inter-
pretation of antibiotic susceptibility testing (AST).1 Laboratories
in Europe are encouraged to change their AST system to facilitate
comparability of AST results. The CLSI has updated its recom-
mendations for interpretation of in vitro drug susceptibility
testing results in the CLSI 2010 and 2011 guidelines; this
update is based on clinical data, pharmacokinetic–pharmacody-
namic (PK–PD) properties and MIC distributions, in part adopting
EUCAST strategies.2,3
In particular for Gram-negative bacilli, significant changes in AST
interpretation are notable. Inhibition zone diameter breakpoints for
Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter
baumannii defining susceptibility to third-generation cephalospor-
ins, carbapenems and fluoroquinolones are significantly higher in
the EUCAST 2011 version compared with CLSI 2009 breakpoints.1,4
Most recently, CLSI recommended higher zone diameter suscepti-
bility breakpoints for third-generation cephalosporins and carba-
penems in its 2010 and 2011 updates, while breakpoints for
fluoroquinolones were not changed.2,3
The main difference between EUCAST and CLSI is the elimin-
ation, or at least a reduction of, the intermediate AST category.
EUCAST has, in part, removed the intermediate zone, because
PKs/PDs and limited clinical data do not support an intermediate
category. Consequently, AST reports are simplified by reporting
an isolate as either susceptible or resistant. This strategy will
change AST reports, mostly by reporting isolates as resistant that
were formerly considered intermediate. Additionally, higher
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diameter breakpoints will enhance increasing resistance rates
reported for Gram-negative bacilli.5,6 The definition of multidrug-
resistant bacteria is commonly based on the presence of resist-
ance to antibiotic agents from several different antibiotic
classes.7 A change in resistance rates of individual classes of anti-
biotic drugs will therefore inevitably influence the rate of
multidrug-resistant isolates reported by the microbiological
laboratory.
Adoption of new guidelines and breakpoints can have a
significanteffectonASTreports of diagnostic laboratories,with con-
comitant changes in antibiotic prescription by clinicians.8 This study
aimed at comparing the new standards with respect to changes in
epidemiological parameters, i.e. reported rates of susceptibility and
resistance of Gram-negative bacteriawhen applying CLSI 2009–11
and EUCAST 2011. The results of this study will support clinical
microbiological laboratories in correct interpretation and antibiotic
therapy recommendations to clinicians during the transition
phase fromtheCLSI systemto theEUCASTsystem. Close interaction
with and information from clinicians is needed to avoid uncertain-
ties in the interpretation of changes in AST reports.
Methods
Clinical isolates
In total, 3713 non-duplicate clinical isolates of Gram-negative bacilli
isolated during a 17 month period from January 2010 to May 2011 in
our clinical microbiological laboratory were included in the study. Our
clinical laboratory primarily serves the 850 bed university hospital of
Zurich. The 3713 isolates comprised 2834 Enterobacteriaceae (1360
Escherichia coli, 424 Klebsiella pneumoniae, 159 Klebsiella oxytoca, 306
Enterobacter cloacae, 75 Enterobacter aerogenes, 87 Citrobacter freundii,
68 Citrobacter koseri, 73 Serratia marcescens, 63 Morganella morganii,
47 Proteus vulgaris, 148 Proteus mirabilis and 24 Hafnia alvei), 656
P. aeruginosa, 160 Stenotrophomonas maltophilia and 63 A. baumannii.
Susceptibility testing
For susceptibility testing, the disc diffusion method according to Kirby–
Bauer was used. Antibiotic discs were obtained from Becton Dickinson
(Franklin Lakes, NJ, USA). Susceptibility testing was done on Mueller–
Hinton agar (bioMe´rieux, Marcy l’E´toile, France) using McFarland 0.5
from overnight cultures followed by incubation at 358C for 16–18 h.
Inhibition zone diameters were determined and recorded in the
automated Sirweb/Sirscan system (i2a, Montpellier, France). Inhibition
zone diameters were interpreted according to EUCAST 2011 and CLSI
2009–11 guidelines, respectively (see Tables 1 and 2).
Comparison of CLSI 2009–11 and EUCAST 2011
breakpoints
Inhibition zone diameters were used to compare CLSI 2009–11 recom-
mended diameter breakpoints with EUCAST 2011 clinical breakpoints for
Enterobacteriaceae. For P. aeruginosa, S. maltophilia and A. baumannii, in-
hibition zone diameter breakpoints as recommended in the CLSI 2009–11
AST guidelines were compared with EUCAST 2011 clinical breakpoints,
since CLSI did not change breakpoints for these species from 2009 to
2011. EUCASTeliminates, in part, the intermediate category for some anti-
biotics such as amoxicillin/clavulanic acid. For other drugs such as ceftriax-
one, an intermediate (or indeterminate) zone is kept but not specifically
mentioned in the EUCAST breakpoint tables. Tables 3 and 4 list CLSI
Table 1. Clinical breakpoint values of CLSI 2009–11 and EUCAST 2011 for AST of Enterobacteriaceae
Drug
Clinical breakpoints (mm)
CLSI 2009 CLSI 2010a CLSI 2011a EUCAST 2011b
S I R S I R S I R S I R
ampicillin ≥17 14–16 ≤13 ≥14 ,14
amoxicillin/clavulanic acid ≥18 14–17 ≤13 ≥17 ,17
cefuroxime ≥18 15–17 ≤14 ≥18 ,18
cefoxitin ≥18 15–17 ≤14 ≥19 ,19
cefpodoxime ≥21 18–20 ≤17 ≥21 ,21
ceftriaxone ≥21 14–20 ≤13 ≥23 20–22 ≤19 ≥23 20–22 ,20
cefepime ≥18 15–17 ≤14 ≥24 21–23 ,21
meropenem ≥16 14–15 ≤13 ≥23 20–22 ≤19 ≥22 16–21 ,16
imipenem ≥16 14–15 ≤13 ≥23 20–22 ≤19 ≥21 15–20 ,15
ertapenem ≥19 16–18 ≤15 ≥23 20–22 ≤19 ≥25 20–24 ,20
tobramycin ≥15 13–14 ≤12 ≥16 14–15 ,14
amikacin ≥17 15–16 ≤14 ≥16 14–15 ,14
gentamicin ≥15 13–14 ≤12 ≥17 15–16 ,15
ciprofloxacin ≥21 16–20 ≤15 ≥22 19–21 ,19
levofloxacin ≥17 14–16 ≤13 ≥22 19–21 ,19
norfloxacin ≥17 13–16 ≤12 ≥22 19–21 ,19
trimethoprim/sulfamethoxazole ≥16 11–15 ≤10 ≥16 13–15 ,13
S, susceptible; I, intermediate; R, resistant.
aCLSI categories without value: interpretation guidelines were not changed compared with the previous version.
bEUCAST categories without value: interpretative category does not exist (intermediate category only).
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2009–11 and EUCAST 2011 clinical breakpoints and note the EUCAST in-
ferred intermediate zone. For certain drugs, e.g. ceftazidime, cefotaxime
and piperacillin/tazobactam, the EUCAST guidelines contain other antibiot-
ic disc loads than the CLSI guidelines.1 Only drugs were included in this
comparison for which the same antibiotic disc loads are recommended
in the CLSI and EUCAST system, i.e. ampicillin, amoxicillin/clavulanic acid,
cefuroxime, cefoxitin, cefpodoxime, ceftriaxone, cefepime, meropenem,
imipenem, ertapenem, tobramycin, amikacin, gentamicin, ciprofloxacin,
levofloxacin, norfloxacin and trimethoprim/sulfamethoxazole.
Results
Enterobacteriaceae species
In aggregate, resistance rates to cefepime, ceftriaxone and ertape-
nem increased from 1.6%, 9.5% and 1.0% (CLSI 2009) to 6.3%,
14.2%and1.6%/2.2%(CLSI 2010/2011andEUCAST2011, respect-
ively; see Table 3).
Due to elimination of the intermediate zone for amoxicillin/
clavulanic acid by EUCAST 2011, the resistance rate (corrected
for natural resistance in several species, e.g. Enterobacter spp.,
Citrobacter freundii) increased from 6.0% to 20.6% comparing
CLSI 2009–11 with EUCAST 2011.
The overall resistance rates to fluoroquinolones moderately
increased, e.g. the resistance rate to levofloxacin increased
from 14.7% to 18.3% comparing CLSI 2009–11 with EUCAST
2011 (see Table 3). Increased fluoroquinolone resistance was
noted for all Enterobacteriaceae species except E. coli, C. koseri
and P. vulgaris, e.g. in E. coli resistance rates to fluoroquinolones
were similar comparing CLSI 2009–11 with EUCAST 2011
(Table 3). The most important species-specific changes are
described below.
E. coli
As observed in the trends for Enterobacteriaceae spp., resistance
rates to cefepime and ceftriaxone increased from 2.1% (CLSI
2009) to 8.2% (EUCAST 2011) and from 9.9% (CLSI 2009) to
13.7% (CLSI 2010/11 and EUCAST 2011), respectively. Due to
elimination of the intermediate zone, the resistance rate for
amoxicillin/clavulanic acid increased from 6.6% to 23.7% com-
paring CLSI 2009–11 with EUCAST 2011 (see Table 3).
K. pneumoniae
Resistance rates to fluoroquinolones increased from 12.0%,
10.1% and 13.2% to 17.5%, 15.8% and 19.8% for ciprofloxacin,
levofloxacin and norfloxacin, respectively, comparing CLSI 2009–
11 with EUCAST 2011.
K. oxytoca
The resistance rate to ceftriaxone markedly increased from 0.6%
(CLSI 2009) to 10.1% (CLSI 2010/2011 and EUCAST 2011).
E. cloacae, E. aerogenes and C. freundii
The resistance rate to cefepime in E. cloacae and E. aerogenes
increased from 1.3% and 0% to 6.9% and 2.6% comparing
CLSI 2009–11 with EUCAST 2011.
The resistance rate to ertapenem in E. cloacae, E. aerogenesand
C. freundii increased from 2.6%, 11.7% and 0% with CLSI 2009/
2010 to 7.2%, 11.7% and 0% for CLSI 2011 and to 10.1%,
14.3% and 1.1% with EUCAST 2011, respectively. Concomitantly,
the susceptibility rate to ertapenem in E. cloacae decreased from
94.8% (CLSI 2009/2010) to 78.4% (CLSI 2011 and EUCAST 2011).
Resistance rates to fluoroquinolones in E. cloacae increased
from 2.6%, 2.3% and 0% to 6.0%, 6.5% and 1.8% for ciprofloxa-
cin, levofloxacin and norfloxacin, respectively, comparing CLSI
2009–11 with EUCAST 2011. For E. aerogenes and C. freundii
the same trends as in E. cloacae were noted.
S. marcescens
The resistance rate for ciprofloxacin remained at 0%. However,
resistance rates to levofloxacin and norfloxacin increased from
0% to 1.4% and 5.3% when applying CLSI 2009–11 standards
compared with EUCAST 2011 standards, respectively.
C. koseri, M. morganii, P. mirabilis, P. vulgaris and H. alvei
Only marginal changes in resistance and susceptibility rates were
demonstrated for C. koseri, M. morganii, P. mirabilis, P. vulgaris
and H. alvei (Table 3).
Table 2. Clinical breakpoint values of CLSI 2009–11 and EUCAST 2011
for AST of glucose non-fermenting Gram-negative bacilli
Species/drug
Clinical breakpoints (mm)
CLSI 2009–11a EUCAST 2011b
S I R S I R
S. maltophilia
trimethoprim/
sulfamethoxazole
≥16 11–15 ≤10 ≥16 ,16
P. aeruginosa
cefepime ≥18 15–17 ≤14 ≥18 ,18
imipenem ≥16 14–15 ≤13 ≥20 18–19 ,18
meropenem ≥16 14–15 ≤13 ≥24 18–23 ,18
tobramycin ≥15 13–14 ≤12 ≥16 ,16
amikacin ≥17 15–16 ≤14 ≥18 15–17 ,15
gentamicin ≥15 13–14 ≤12 ≥15 ,15
ciprofloxacin ≥21 16–20 ≤15 ≥25 20–24 ,20
levofloxacin ≥17 14–16 ≤13 ≥20 17–19 ,15
A. baumannii
imipenem ≥16 14–15 ≤13 ≥23 18–22 ,18
meropenem ≥16 14–15 ≤13 ≥21 16–20 ,16
tobramycin ≥15 13–14 ≤12 ≥17 ,17
amikacin ≥17 15–16 ≤14 ≥18 16–17 ,16
gentamicin ≥15 13–14 ≤12 ≥17 ,17
ciprofloxacin ≥21 16–20 ≤15 ≥21 ,21
levofloxacin ≥17 14–16 ≤13 ≥21 19–20 ,19
S, susceptible; I, intermediate; R, resistant.
aCLSI 2009–11 guidelines were not changed.
bEUCAST categories without value: interpretative category does not exist
(intermediate category only).
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Table 3. Assignment of Enterobacteriaceae clinical isolates to interpretative category according to CLSI 2009–11 and EUCAST 2011a
Species/drug
Assignment of clinical isolates (%) to antibiotic susceptibility interpretative categories
CLSI 2009 CLSI 2010 CLSI 2011 EUCAST 2011
S I R S I R S I R S I R
E. coli
ampicillin 38.7 8.5 56.8 43.2 56.8
amoxicillin/clavulanic acid 76.3 15.5 6.6 76.3 23.7
cefuroxime 82.8 2.5 14.7 82.8 17.2
cefoxitin 94.9 2.1 3.4 94.2 5.5
cefpodoxime 83.7 0.4 15.9 83.7 16.3
ceftriaxone 85.4 4.3 9.9 84.8 1.2 13.7 84.8 1.2 13.7
cefepime 94.0 3.3 2.1 88.8 2.5 8.2
meropenem 99.8 0.0 0.0 99.4 0.4 0.0 99.5 0.3 0.0
imipenem 99.9 0.0 0.0 99.5 0.4 0.1 99.8 0.2 0.0
ertapenem 99.1 0.1 0.1 98.8 0.2 0.3 98.7 0.2 0.4
tobramycin 84.0 2.8 13.2 83.0 2.2 14.8
amikacin 97.1 1.8 1.1 98.1 1.0 1.0
gentamicin 86.6 0.4 13.0 86.2 0.5 13.4
ciprofloxacin 70.8 1.6 27.5 70.3 1.4 28.3
levofloxacin 72.2 2.4 25.2 68.7 2.4 28.8
norfloxacin 75.5 0.9 23.4 74.2 0.7 24.9
trimethoprim/sulfamethoxazole 63.5 0.8 35.6 63.5 0.3 36.2
K. pneumoniae
amoxicillin/clavulanic acid 80.4 9.8 5.3 80.4 19.6
cefuroxime 78.9 4.1 17.0 78.9 21.1
cefoxitin 89.5 7.9 4.5 87.4 12.4
cefpodoxime 83.7 1.0 15.3 83.7 16.3
ceftriaxone 85.8 3.8 10.1 84.4 1.7 13.7 84.4 1.7 13.7
cefepime 94.3 2.6 2.9 87.3 3.1 9.3
meropenem 97.6 0.7 1.4 97.6 0.0 2.1 97.6 0.0 2.1
imipenem 97.6 0.5 1.7 97.1 0.5 2.2 97.6 0.5 1.7
ertapenem 97.6 0.0 2.1 97.4 0.2 2.1 95.5 1.9 2.4
tobramycin 85.1 0.7 14.2 84.7 0.7 14.6
amikacin 96.5 0.9 2.6 97.4 0.9 1.7
gentamicin 91.4 0.5 8.1 90.4 1.0 8.6
ciprofloxacin 79.1 8.9 12.0 77.6 4.8 17.5
levofloxacin 87.7 2.1 10.1 74.8 9.4 15.8
norfloxacin 81.0 5.8 13.2 74.4 5.8 19.8
trimethoprim/sulfamethoxazole 74.3 1.7 24.0 74.3 1.7 24.0
K. oxytoca
amoxicillin/clavulanic acid 82.9 6.3 3.8 82.9 17.1
cefuroxime 80.4 1.9 17.7 80.4 19.6
cefoxitin 98.7 1.3 0.6 98.1 1.9
cefpodoxime 90.5 1.9 7.6 90.5 9.5
ceftriaxone 88.7 10.7 0.6 86.8 3.1 10.1 86.8 3.1 10.1
cefepime 99.4 0.6 0.0 97.5 1.9 0.6
meropenem 99.4 0.0 0.0 99.4 0.0 0.0 99.4 0.0 0.0
imipenem 100 0.0 0.0 100 0.0 0.0 100 0.0 0.0
ertapenem 99.4 0.0 0.0 99.4 0.0 0.0 99.4 0.0 0.0
tobramycin 96.2 0.6 3.1 96.2 0.6 3.1
amikacin 99.4 0.0 0.6 99.4 0.6 0.0
gentamicin 96.2 0.6 3.2 94.9 1.3 3.8
Continued
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Table 3. Continued
Species/drug
Assignment of clinical isolates (%) to antibiotic susceptibility interpretative categories
CLSI 2009 CLSI 2010 CLSI 2011 EUCAST 2011
S I R S I R S I R S I R
ciprofloxacin 96.8 3.2 0.0 94.9 3.2 1.9
levofloxacin 98.7 0.6 0.6 94.3 3.8 1.9
norfloxacin 100 0.0 0.0 100 0.0 0.0
trimethoprim/sulfamethoxazole 91.8 0.0 8.2 91.8 0.0 8.2
E. cloacae
cefuroxime 64.0 2.3 33.7 64.0 36.0
cefpodoxime 55.8 10.2 34.0 55.8 44.2
ceftriaxone 70.2 11.1 18.7 68.5 3.6 27.9 68.5 3.6 27.9
cefepime 95.7 3.0 1.3 84.2 8.9 6.9
meropenem 98.0 0.7 1.3 97.1 0.0 2.9 97.1 1.0 2.0
imipenem 98.7 0.3 1.0 93.1 5.0 2.0 97.7 1.0 1.3
ertapenem 94.8 2.6 2.6 85.6 7.2 7.2 78.4 11.4 10.1
tobramycin 90.2 0.3 9.5 89.5 0.7 9.8
amikacin 98.0 1.3 0.7 98.4 1.3 0.3
gentamicin 92.4 4.3 3.3 90.8 1.6 7.6
ciprofloxacin 91.1 6.3 2.6 90.1 4.0 6.0
levofloxacin 95.8 2.0 2.3 90.6 2.9 6.5
norfloxacin 98.2 1.8 0.0 98.2 0.0 1.8
trimethoprim/sulfamethoxazole 87.5 2.3 10.2 87.5 1.0 11.6
E. aerogenes
cefuroxime 59.7 1.3 39.0 59.7 40.3
cefpodoxime 59.7 0.0 40.3 59.7 40.3
ceftriaxone 68.8 18.2 13.0 63.6 6.5 29.9 63.6 6.5 29.9
cefepime 97.4 2.6 0.0 92.2 5.2 2.6
meropenem 97.4 2.6 0.0 88.3 0.0 11.7 88.3 9.1 2.6
imipenem 96.1 3.9 0.0 81.8 9.1 9.1 88.3 10.4 1.3
ertapenem 88.3 0.0 11.7 84.4 3.9 11.7 76.6 9.1 14.3
tobramycin 98.7 0.0 1.3 98.7 0.0 1.3
amikacin 100 0.0 0.0 100 0.0 0.0
gentamicin 98.7 0.0 1.3 96.0 2.7 1.3
ciprofloxacin 92.0 4.0 4.0 90.7 2.7 6.7
levofloxacin 96.0 1.3 2.7 90.7 4.0 5.3
norfloxacin 100 0.0 0.0 100 0.0 0.0
trimethoprim/sulfamethoxazole 96.1 2.6 1.3 96.1 2.6 1.3
C. freundii
cefuroxime 69.0 4.6 26.4 69.0 31.0
cefpodoxime 49.4 13.8 36.8 49.4 50.6
ceftriaxone 74.7 6.9 18.4 71.3 4.6 24.1 71.3 4.6 24.1
cefepime 100 0.0 0.0 95.4 4.6 0.0
meropenem 100 0.0 0.0 100 0.0 0.0 100 0.0 0.0
imipenem 100 0.0 0.0 93.1 6.9 0.0 100 0.0 0.0
ertapenem 97.7 0.0 0.0 95.4 2.3 0.0 88.5 8.0 1.1
tobramycin 98.9 0.0 1.1 97.7 1.1 1.1
amikacin 100 0.0 0.0 100 0.0 0.0
gentamicin 100 0.0 0.0 97.7 2.3 0.0
ciprofloxacin 93.1 2.3 4.6 93.1 0.0 6.9
levofloxacin 94.3 1.1 4.6 90.8 2.3 6.9
norfloxacin 94.1 5.9 0.0 94.1 0.0 5.9
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Table 3. Continued
Species/drug
Assignment of clinical isolates (%) to antibiotic susceptibility interpretative categories
CLSI 2009 CLSI 2010 CLSI 2011 EUCAST 2011
S I R S I R S I R S I R
trimethoprim/sulfamethoxazole 90.8 0.0 9.2 90.8 0.0 9.2
C. koseri
amoxicillin/clavulanic acid 95.6 0.0 4.4 95.6 4.4
cefuroxime 88.4 7.2 4.3 88.4 11.6
cefoxitin 97.1 2.9 2.9 94.1 5.9
cefpodoxime 98.5 0.0 1.5 98.5 1.5
ceftriaxone 100 0.0 0.0 100 0.0 0.0 100 0.0 0.0
cefepime 100 0.0 0.0 100 0.0 0.0
meropenem 100 0.0 0.0 100 0.0 0.0 100 0.0 0.0
imipenem 100 0.0 0.0 98.5 1.5 0.0 100 0.0 0.0
ertapenem 100 0.0 0.0 100 0.0 0.0 100 0.0 0.0
tobramycin 100 0.0 0.0 100 0.0 0.0
amikacin 98.5 1.5 0.0 100 0.0 0.0
gentamicin 100 0.0 0.0 100 0.0 0.0
ciprofloxacin 100 0.0 0.0 98.5 1.5 0.0
levofloxacin 100 0.0 0.0 100 0.0 0.0
norfloxacin 100 0.0 0.0 100 0.0 0.0
trimethoprim/sulfamethoxazole 98.5 0.0 1.5 98.5 0.0 1.5
S. marcescens
cefpodoxime 87.7 4.1 8.2 87.7 12.3
ceftriaxone 94.5 4.1 1.4 93.2 2.7 4.1 93.2 2.7 4.1
cefepime 100 0.0 0.0 98.6 1.4 0.0
meropenem 100 0.0 0.0 100 0.0 0.0 100 0.0 0.0
imipenem 100 0.0 0.0 95.9 2.7 1.4 98.6 1.4 0.0
ertapenem 97.3 1.4 0.0 97.3 0.0 1.4 97.3 0.0 1.4
tobramycin 95.9 2.7 1.4 91.8 5.5 2.7
amikacin 100 0.0 0.0 100 0.0 0.0
gentamicin 100 0.0 0.0 100 0.0 0.0
ciprofloxacin 94.5 5.5 0.0 90.4 9.6 0.0
levofloxacin 98.6 1.4 0.0 90.4 8.2 1.4
norfloxacin 100 0.0 0.0 89.5 5.3 5.3
trimethoprim/sulfamethoxazole 94.5 1.4 4.1 94.5 1.4 4.1
M. morganii
cefpodoxime 87.3 1.6 11.1 87.3 12.7
ceftriaxone 98.4 0.0 1.6 98.4 0.0 1.6 98.4 0.0 1.6
cefepime 100 0.0 0.0 98.4 1.6 0.0
meropenem 100 0.0 0.0 100 0.0 0.0 100 0.0 0.0
imipenem 100 0.0 0.0 74.6 23.8 1.6 95.2 4.8 0.0
ertapenem 100 0.0 0.0 100 0.0 0.0 100 0.0 0.0
tobramycin 95.2 3.2 1.6 93.7 4.8 1.6
amikacin 100 0.0 0.0 100 0.0 0.0
gentamicin 88.9 0.0 11.1 87.3 1.6 11.1
ciprofloxacin 87.3 3.2 9.5 87.3 0.0 12.7
levofloxacin 90.5 0.0 9.5 84.1 3.2 12.7
norfloxacin 94.7 0.0 5.3 89.5 5.3 5.3
trimethoprim/sulfamethoxazole 79.4 1.6 19.0 79.4 1.6 19.0
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Table 3. Continued
Species/drug
Assignment of clinical isolates (%) to antibiotic susceptibility interpretative categories
CLSI 2009 CLSI 2010 CLSI 2011 EUCAST 2011
S I R S I R S I R S I R
P. vulgaris
amoxicillin/clavulanic acid 93.6 2.1 4.3 93.6 6.4
cefoxitin 100 4.3 0.0 95.7 4.3
cefpodoxime 95.7 0.0 4.3 95.7 4.3
ceftriaxone 97.9 0.0 2.1 97.9 0.0 2.1 97.9 0.0 2.1
cefepime 97.9 2.1 0.0 97.9 0.0 2.1
meropenem 100 0.0 0.0 100 0.0 0.0 100 0.0 0.0
imipenem 100 0.0 0.0 87.2 10.6 2.1 97.9 2.1 0.0
ertapenem 100 0.0 0.0 100 0.0 0.0 100 0.0 0.0
tobramycin 100 0.0 0.0 100 0.0 0.0
amikacin 100 0.0 0.0 100 0.0 0.0
gentamicin 100 0.0 0.0 100 0.0 0.0
ciprofloxacin 100 0.0 0.0 100 0.0 0.0
levofloxacin 100 0.0 0.0 100 0.0 0.0
norfloxacin 100 0.0 0.0 100 0.0 0.0
trimethoprim/sulfamethoxazole 91.5 0.0 8.5 91.5 0.0 8.5
P. mirabilis
ampicillin 63.5 4.5 35.1 64.9 35.1
amoxicillin/clavulanic acid 92.6 2.7 6.1 92.6 7.4
cefuroxime 94.6 1.4 4.1 94.6 5.4
cefoxitin 97.3 1.4 1.4 97.3 2.7
cefpodoxime 95.3 0.0 4.7 95.3 4.7
ceftriaxone 94.6 1.4 0.7 94.6 0.0 2.0 94.6 0.0 2.0
cefepime 99.3 0.0 0.7 98.6 0.0 1.4
meropenem 100 0.0 0.0 99.3 0.0 0.7 99.3 0.7 0.0
imipenem 99.3 0.0 0.7 94.5 4.8 0.7 98.6 0.7 0.7
ertapenem 98.0 0.0 0.7 98.0 0.0 0.7 97.3 0.7 0.7
tobramycin 92.6 0.7 6.8 89.9 3.4 6.8
amikacin 97.3 1.4 1.4 97.3 2.0 0.7
gentamicin 85.8 1.4 12.8 84.5 1.4 14.2
ciprofloxacin 85.1 5.4 8.8 83.8 2.7 12.8
levofloxacin 90.5 2.7 6.8 84.5 4.1 11.5
norfloxacin 86.1 8.3 2.8 80.6 5.6 11.1
trimethoprim/sulfamethoxazole 75.0 1.4 23.6 75.0 0.7 24.3
H. alvei
cefuroxime 62.5 4.2 33.3 62.5 37.5
cefpodoxime 70.8 8.3 20.8 70.8 29.2
ceftriaxone 87.5 0.0 12.5 79.2 8.3 12.5 79.2 8.3 12.5
cefepime 100 0.0 0.0 100 0.0 0.0
meropenem 100 0.0 0.0 100 0.0 0.0 100 0.0 0.0
imipenem 100 0.0 0.0 100 0.0 0.0 100 0.0 0.0
ertapenem 100 0.0 0.0 100 0.0 0.0 100 0.0 0.0
tobramycin 100 0.0 0.0 100 0.0 0.0
amikacin 100 0.0 0.0 100 0.0 0.0
gentamicin 100 0.0 0.0 100 0.0 0.0
ciprofloxacin 100 0.0 0.0 100 0.0 0.0
levofloxacin 100 0.0 0.0 100 0.0 0.0
Continued
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P. aeruginosa
Resistance rates to cefepime, imipenem and meropenem in
P. aeruginosa increased from 12.2%, 25.5% and 20.6% to
19.8%, 30.4% and 27.7% comparing CLSI 2009–11 standards
with EUCAST 2011 standards, respectively (see Table 4).
Resistance rates to gentamicin increased from 18.6% to 25.2%
with CLSI 2009–11 standards compared with EUCAST 2011 stan-
dards due to elimination of the intermediate category by EUCAST.
Resistance rates to ciprofloxacin and levofloxacin increased
from 15.9% and 21.3% to 29.7% and 30.8% with CLSI 2009–11
standards compared with EUCAST 2011 standards, respectively.
S. maltophilia
Trimethoprim/sulfamethoxazole is the only substance for which
EUCAST 2011 provides AST breakpoints. No significant differences
in the CLSI 2011 system were found except the elimination of
the intermediate category by EUCAST and a resulting slight
increase in the resistant category (9.4% and 10.6% resistance
rate comparing CLSI 2009–11 with EUCAST 2011; see Table 4).
A. baumannii complex
Resistance rates to tobramycin and gentamicin increased from
15.9% and 25.4% to 34.9% and 44.4% comparing CLSI 2009–
11 standards with EUCAST 2011 standards, while the resistance
rate to amikacin remained unchanged (34.9%). In the case of
tobramycin and gentamicin, the increased resistance rate
results from the elimination of the intermediate zone in the
EUCAST system. The gentamicin susceptibility rate was compar-
able in both the CLSI 2009–11 and the EUCAST 2011 system
(58.7% and 55.6%, respectively). In the case of tobramycin,
however, the increased resistance rate was accompanied by a
decrease in the susceptibility rate (84.1% with the CLSI 2009–
11 versus 77.8% with the EUCAST 2011 system; see Table 4).
Discussion
Many European laboratories are currently preparing to implement
the new EUCAST guidelines for AST.1 Besides the national AST
systems (e.g. in Germany, France, theUKand Sweden),many labora-
tories, in particular in countries without a national AST system, have
beenusing CLSI guidelines formany years.2–4Prior to implementing
new guidelines in the diagnostic microbiology laboratory, the con-
sequences of changed AST reports need to be considered to
prevent misunderstandings in interpretation. The introduction of
new guidelines should be accompanied by communicating the
scientific rationale and the practical implications of changes
in AST reporting.9 In this study the interpretation of AST for
Table 3. Continued
Species/drug
Assignment of clinical isolates (%) to antibiotic susceptibility interpretative categories
CLSI 2009 CLSI 2010 CLSI 2011 EUCAST 2011
S I R S I R S I R S I R
norfloxacin 100 0.0 0.0 100 0.0 0.0
trimethoprim/sulfamethoxazole 100 0.0 0.0 100 0.0 0.0
All Enterobacteriaceae speciesb
ampicillin 41.2 4.2 54.6 45.4 54.6
amoxicillin/clavulanic acid 79.4 12.3 6.0 79.4 20.6
cefuroxime 77.2 3.8 19.1 77.2 22.8
cefoxitin 94.7 3.2 3.2 93.6 6.4
cefpodoxime 80.6 2.2 17.2 80.6 19.4
ceftriaxone 85.2 5.3 9.5 84.0 1.8 14.2 84.0 1.8 14.2
cefepime 95.9 2.4 1.6 90.6 3.1 6.3
meropenem 99.4 0.2 0.4 98.8 0.2 1.0 98.9 0.5 0.6
imipenem 99.4 0.2 0.4 96.7 2.3 1.0 98.8 0.8 0.5
ertapenem 98.6 0.4 1.0 97.3 1.1 1.6 95.7 2.2 2.2
tobramycin 88.2 1.7 10.1 87.2 1.7 11.0
amikacin 97.6 1.3 1.1 98.3 0.9 0.8
gentamicin 90.3 0.8 8.9 89.4 0.9 9.7
ciprofloxacin 80.3 3.6 16.1 79.3 2.5 18.2
levofloxacin 83.3 2.0 14.7 78.0 3.7 18.3
norfloxacin 82.4 2.0 15.6 80.0 1.8 18.3
trimethoprim/sulfamethoxazole 74.5 1.1 24.4 74.5 0.7 24.8
S, susceptible; I, intermediate; R, resistant.
aDrugs to which species are naturally resistant are not listed. CLSI categories without value: interpretation guidelines were not changed compared
with the previous version. EUCAST categories without value: interpretative category does not exist (applies to intermediate category only).
bValues were corrected for natural resistance.
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Gram-negative bacilli using the CLSI guidelines of 2009–11 and
the EUCAST 2011 system was investigated.
Implementation of EUCAST 2011 will lead to significantly
more isolates of Gram-negative species being reported resistant
to extended-spectrum cephalosporins (ceftriaxone, cefepime),
carbapenems and fluoroquinolones (Tables 1 and 2). The same
applies to the CLSI 2011 standards. Since usage volume and
resistance rate for an individual drug are generally linked,
higher numbers of Gram-negative bacilli reported resistant to
third-generation cephalosporins, carbapenems and fluoroquino-
lones will most likely lead to an increased therapeutic usage
volume and thus increased selection pressure on other anti-
microbial classes or drugs such as aminoglycosides, trimetho-
prim/sulfamethoxazole, fosfomycin or nitrofurantoin.10–12
The effects of a change from CLSI 2009 to CLSI 2010/2011 or
fromCLSI 2009 to EUCAST 2011differ between Enterobacteriaceae
species: for example, while the resistance rate for fluoroquinolones
in E. coli remains almost unchanged, E. cloacae and K. pneumoniae
are more frequently reported as resistant to these antibiotics using
EUCAST 2011 (Table 3). This finding is most probably related to the
different natural diameter distributions of individual Enterobacter-
iaceae species as compared with the breakpoints, which are
defined for the whole Enterobacteriaceae family. In the EUCAST
diameter distribution tables (available at http://www.eucast.org/
zone_diameter_distributions/), the putative wild-type population
of E. cloacae, for example, shows a diameter range of 20–
38 mm and 19–33 mm for ciprofloxacin and levofloxacin, re-
spectively, while the putative wild-type population of E. coli
shows a diameter range of 25–42 mm and 26–39 mm for cipro-
floxacin and levofloxacin, respectively. Considering the uniform re-
sistant breakpoint definitions for both drugs and species, the
lower average diameters of E. cloacae readings explain the
greater increase in fluoroquinolone resistance rates compared
with E. coli. We suggest that species-adapted breakpoints for
Enterobacteriaceae species would eliminate these artefacts and
improve interpretation of AST.
Reportedly the number of extended-spectrum b-lactamase
(ESBL)-producing strains isolated in the clinical laboratory is
increasing, and ESBL-producing isolates are frequently treated
with carbapenems, thereby selecting for carbapenemase-
producing strains.13–15 The EUCAST 2011 and CLSI 2011 guide-
lines have led to a paradigm change in AST reporting of ESBL-
producing isolates. Until 2009 the CLSI guidelines recommended
reporting in vitro intermediate and susceptible AST results for
third- and fourth-generation cephalosporins as resistant in con-
firmed ESBL producers. In its 2008 expert rules EUCAST recom-
mended changing the interpretation of AST results of third- and
fourth-generation cephalosporins from ‘susceptible’ to ‘inter-
mediate’ and from ‘intermediate’ to ‘resistant’ for confirmed
ESBL producers.16 These recommendations have been aban-
doned. Classification as susceptible, intermediate or resistant is
now based on the reading of inhibition zone diameters alone,
and not on interpretative reading, i.e. considering the underlying
resistance mechanism.17,18 Based on the new EUCAST and CLSI
recommendations, a significant fraction of ESBL-producing
strains will be categorized as susceptible to third- and fourth-
generation cephalosporins.19 In a recent study we showed cef-
tazidime to be more frequently categorized as susceptible
(22.9%) in ESBL producers, whereas the susceptibility rate to cefo-
taxime was low (0.8%). This finding is probably due to the high
prevalence of CTX-M ESBL types in our study population, which
resembles the epidemiological situation in Europe.20 One effect
of implementing the new EUCASTand CLSI guidelines is treatment
of ESBLs with third- and fourth-generation cephalosporins, and
thus less frequent use of carbapenems, reducing selection pres-
sure on this increasingly used drug family.21 In contrast, the
increased diameter breakpoints for third- and fourth-generation
cephalosporins in EUCAST will result in higher resistance rates
reported for those drugs. Carbapenems will most likely be
chosen to serve as alternative substances due to their currently
low resistance rates, broad activity and low side effects. It is diffi-
cult to predict which effect will prevail: less frequent use of carba-
penems due to using third- and fourth-generation cephalosporins
for ESBL-producing isolates, ormore frequent use of carbapenems
due to higher resistance rates reported for third- and fourth-
generation cephalosporins resulting from increased diameter
breakpoints. One limitation of this study is the exclusion of ceftazi-
dime, cefotaxime and piperacillin/tazobactam. Analyses were
done in a routine microbiological laboratory using CLSI disc con-
tents. EUCAST uses lower disc loads than CLSI (10 mg/disc, 5 mg/
disc and 30/6 mg/disc EUCAST versus 30 mg/disc, 30 mg/disc and
100/10 mg/disc CLSI for ceftazidime, cefotaxime and piperacillin/
tazobactam, respectively), making interpretation of diameters
Table 4. Assignment of glucose non-fermenting Gram-negative bacilli
clinical isolates to interpretative categories according to CLSI 2009–11
and EUCAST 2011 guidelines
Species/drug
Assignment of clinical isolates (%)
to antibiotic susceptibility
interpretative categories
CLSI 2009–11 EUCAST 2011a
S I R S I R
P. aeruginosa
cefepime 80.2 7.6 12.2 80.2 19.8
imipenem 71.7 2.4 25.5 67.0 2.3 30.4
meropenem 73.5 3.5 20.6 63.0 8.8 27.7
tobramycin 87.5 2.3 10.2 86.3 13.7
amikacin 80.3 4.0 15.7 76.6 7.6 15.7
gentamicin 74.8 6.6 18.6 74.8 25.2
ciprofloxacin 72.9 10.7 15.9 63.0 6.9 29.7
levofloxacin 69.2 9.5 21.3 62.8 6.4 30.8
S. maltophilia
trimethoprim/sulfamethoxazole 89.4 1.3 9.4 89.4 10.6
A. baumannii
imipenem 65.1 1.6 33.3 65.1 0.0 34.9
meropenem 66.7 0.0 33.3 61.9 4.8 33.3
tobramycin 84.1 0.0 15.9 77.8 34.9
amikacin 65.1 0.0 34.9 65.1 0.0 34.9
gentamicin 58.7 15.9 25.4 55.6 44.4
ciprofloxacin 51.6 3.2 45.2 51.6 48.4
levofloxacin 58.1 1.6 40.3 54.8 1.6 43.5
S, susceptible; I, intermediate; R, resistant.
aEUCAST categories without value: interpretative category does not exist
(applies to intermediate category only).
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with both systems impossible. Taking into account the importance
of piperacillin/tazobactam in clinical practice, more studies are
needed to analyse further the impact of the new AST guidelines.
The number of useful antimicrobial treatment options for
glucose non-fermenting Gram-negative bacilli like P. aeruginosa
and A. baumannii will probably decrease after implementation
of the EUCAST guidelines due to higher resistance rates. Especial-
ly for P. aeruginosa, resistance rates of cefepime, carbapenems
and fluoroquinolones will increase (Table 4). Resistance rates of
aminoglycosides in P. aeruginosa are hardly affected by changing
from CLSI to EUCAST guidelines (Table 4). These classes of drugs
may therefore become a frequently chosen alternative, but will
hardly be used as monotherapy.
No standard definitions exist to define Gram-negative bacilli as
multidrug resistant, but most systems are based on the detection
ofnon-susceptibility to several antibiotic classes.7 Following imple-
mentation of the CLSI 2011 and EUCAST 2011 guidelines more
Gram-negative bacilli will be reported as multidrug resistant,
resulting in higher rates of patients in isolation and, concomitantly,
higher costs.22 A higher rate ofmultidrug-resistant Gram-negative
bacilli will not only result in higher costs for hospitals and hospital
hygienemeasures, butwill also result inmore confirmatory testing
in the laboratory.
AST reports influence prescription policy and antibiotic use.8
Implementation of EUCAST guidelines will affect antibiotic pre-
scription, in part because of the partial elimination of the inter-
mediate category. Defining isolates as resistant that were
formerly considered intermediate will most likely lead clinicians
to use other antimicrobial classes.
This study was limited to the epidemiological situation in the
Zurich region with low to moderate levels of resistance. The
increase in resistance rates reported due to changes in guidelines
may be more prominent in populations with higher levels of
resistance, e.g. the Mediterranean region, since diameter distri-
butions are shifted to lower mean values. In contrast, a lesser
increase of reported resistance rates may be seen in regions
with low resistance levels, such as Scandinavia.
Implementation of the EUCASTstandards for ASTmakes results
in Europemore comparable, incorporating PK–PD studies and clin-
ical data, e.g. the possible use of extended-spectrumcephalospor-
ins versus carbapenems for ESBL-producing isolates.1 However,
evidence-based clinical studies should further accompany and
validate proposed changes in guidelines. During implementation
of the EUCAST system, laboratories should be aware of the
implications of modified AST reports on antibiotic prescription
policy. Information from clinicians on changes in guidelines result-
ing in apparently increased resistance rates may help to prevent
excessive use of reserve antibiotic drugs. Antibiotic stewardship
has been proven to effectively control antibiotic prescription,
resulting in lower resistance rates.23 Considering a changed
description of antimicrobial drug susceptibility in Gram-negative
bacilli with higher resistance rates following implementation of
the CLSI 2011 and EUCAST 2011 standards, the need for antibiotic
stewardship must once more be emphasized.
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